Back to top

Cytokinetics, Inc. Enters Oversold Territory
October 08, 2013

Read MoreHide Full Article

Cytokinetics, Inc.’s (CYTK - Free Report) share price has entered into oversold territory with an RSI value of 28.94. The Zacks Consensus Estimate on Cytokinetics, Inc.’s earnings for the full year period has profit by 0.00 cents over the past two months to $-1.71 per share. Currently, Cytokinetics, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (CYTK - Free Report) after its recent drop.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Cytokinetics, Incorporated (CYTK) - free report >>


More from Zacks Tale of the Tape

You May Like